New hope for eczema sufferers as FDA approves Eli Lilly’s EBGLYSS
Eli Lilly and Company (Lilly) has secured approval from the U.S. Food and Drug Administration (FDA) for its new biologic treatment, EBGLYSS (lebrikizumab-lbkz), for moderate-to-severe atopic dermatitis in adults and children aged 12 and older. This biologic drug is positioned as a first-line treatment option, promising substantial relief for patients whose eczema is not well […]